Highlights Photocure ASA

Equities

PHO

NO0010000045

Real-time Oslo Bors Other stock markets 06:25:59 2024-04-29 am EDT			5-day change	1st Jan Change
57 ^NOK	+2.89%		+4.78%	-15.43%

Apr. 08	Photocure ASA Announces its Participation in the Congress, and Two Abstract Presentations at the 2024 European Association of Urology Congress in Paris, France	CI
Mar. 28	Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Photocure ASA Announces its Participation in the Congress, and Two Abstract Presentations at the 2024 European Association of Urology Congress in Paris, France	Apr. 08	CI
Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy	Mar. 28	CI
Photocure ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 21	CI
Photocure Partner Wins Chinese Regulatory Nod for New Drug Application for Bladder Cancer Diagnosis Drug	Nov. 29	MT
Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China	Nov. 29	CI
Photocure ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint	23-08-11	CI
Photocure ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Tranche Update on Photocure ASA (OB:PHO)'s Equity Buyback Plan announced on June 3, 2022.	23-08-08	CI
Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China	23-07-05	CI
Photocure ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Tranche Update on Photocure ASA (OB:PHO)'s Equity Buyback Plan announced on June 3, 2022.	23-05-09	CI
Photocure ASA's Equity Buyback announced on June 3, 2022, has expired with 29,435 shares, representing 0.11% for NOK 3.06 million.	23-05-02	CI
Photocure Asa Announces New Data Presented At EAU 2023 Highlight the Effects of Blue Light Cystoscopy in Bladder Cancer	23-03-13	CI
Photocure ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-23	CI
Tranche Update on Photocure ASA (OB:PHO)'s Equity Buyback Plan announced on June 3, 2022.	23-02-23	CI
Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC	23-02-20	CI
Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week	23-01-02	CI
Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy	22-12-05	CI
Photocure ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Photocure ASA

Equities

PHO

NO0010000045

Highlights

Filters